Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment

J. H. Karnes, C. W. McDonough, Y. Gong, T. T. Vo, T. Y. Langaee, A. B. Chapman, J. G. Gums, A. L. Beitelshees, Kent R Bailey, J. L. Del-Aguila, E. A. Boerwinkle, C. J. Pepine, Stephen T Turner, J. A. Johnson, R. M. Cooper-Dehoff

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Thiazide-induced potassium loss may contribute to new onset diabetes (NOD). KCNJ1 encodes a potassium channel and one study observed that a KCNJ1 single-nucleotide polymorphism (SNP) was associated with changes in fasting glucose (FG) during hydrochlorothiazide (HCTZ) treatment. We used linear regression to test association of KCNJ1 SNPs and haplotypes with FG changes during HCTZ treatment in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. We used logistic regression to test association of KCNJ1 variation with NOD in HCTZ-treated patients from the International Verapamil SR Trandolapril Study (INVEST). Multivariate regression analyses were performed by race/ethnicity with false discovery rate (FDR) correction. In PEAR blacks, a KCNJ1 SNP was associated with increased FG during HCTZ treatment (beta=8.47, P FDR =0.009). KCNJ1 SNPs and haplotypes were associated with NOD risk in all INVEST race/ethnic groups (strongest association: odds ratio 2.14 (1.31-3.53), P FDR =0.03). Our findings support that KCNJ1 variation is associated with HCTZ-induced dysglycemia and NOD.

Original languageEnglish (US)
Pages (from-to)430-436
Number of pages7
JournalPharmacogenomics Journal
Volume13
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Hydrochlorothiazide
trandolapril
Fasting
Single Nucleotide Polymorphism
Glucose
Pharmacogenetics
Verapamil
Haplotypes
Antihypertensive Agents
Thiazides
Therapeutics
Potassium Channels
Ethnic Groups
Linear Models
Potassium
Multivariate Analysis
Logistic Models
Odds Ratio
Regression Analysis

Keywords

  • diabetes mellitus
  • hydrochlorothiazide
  • hypertension
  • KCNJ1
  • pharmacogenetics
  • ROMK1

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Karnes, J. H., McDonough, C. W., Gong, Y., Vo, T. T., Langaee, T. Y., Chapman, A. B., ... Cooper-Dehoff, R. M. (2013). Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics Journal, 13(5), 430-436. https://doi.org/10.1038/tpj.2012.34

Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. / Karnes, J. H.; McDonough, C. W.; Gong, Y.; Vo, T. T.; Langaee, T. Y.; Chapman, A. B.; Gums, J. G.; Beitelshees, A. L.; Bailey, Kent R; Del-Aguila, J. L.; Boerwinkle, E. A.; Pepine, C. J.; Turner, Stephen T; Johnson, J. A.; Cooper-Dehoff, R. M.

In: Pharmacogenomics Journal, Vol. 13, No. 5, 10.2013, p. 430-436.

Research output: Contribution to journalArticle

Karnes, JH, McDonough, CW, Gong, Y, Vo, TT, Langaee, TY, Chapman, AB, Gums, JG, Beitelshees, AL, Bailey, KR, Del-Aguila, JL, Boerwinkle, EA, Pepine, CJ, Turner, ST, Johnson, JA & Cooper-Dehoff, RM 2013, 'Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment', Pharmacogenomics Journal, vol. 13, no. 5, pp. 430-436. https://doi.org/10.1038/tpj.2012.34
Karnes, J. H. ; McDonough, C. W. ; Gong, Y. ; Vo, T. T. ; Langaee, T. Y. ; Chapman, A. B. ; Gums, J. G. ; Beitelshees, A. L. ; Bailey, Kent R ; Del-Aguila, J. L. ; Boerwinkle, E. A. ; Pepine, C. J. ; Turner, Stephen T ; Johnson, J. A. ; Cooper-Dehoff, R. M. / Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. In: Pharmacogenomics Journal. 2013 ; Vol. 13, No. 5. pp. 430-436.
@article{d0b2e326d21f4dae848ff1b4598b31f0,
title = "Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment",
abstract = "Thiazide-induced potassium loss may contribute to new onset diabetes (NOD). KCNJ1 encodes a potassium channel and one study observed that a KCNJ1 single-nucleotide polymorphism (SNP) was associated with changes in fasting glucose (FG) during hydrochlorothiazide (HCTZ) treatment. We used linear regression to test association of KCNJ1 SNPs and haplotypes with FG changes during HCTZ treatment in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. We used logistic regression to test association of KCNJ1 variation with NOD in HCTZ-treated patients from the International Verapamil SR Trandolapril Study (INVEST). Multivariate regression analyses were performed by race/ethnicity with false discovery rate (FDR) correction. In PEAR blacks, a KCNJ1 SNP was associated with increased FG during HCTZ treatment (beta=8.47, P FDR =0.009). KCNJ1 SNPs and haplotypes were associated with NOD risk in all INVEST race/ethnic groups (strongest association: odds ratio 2.14 (1.31-3.53), P FDR =0.03). Our findings support that KCNJ1 variation is associated with HCTZ-induced dysglycemia and NOD.",
keywords = "diabetes mellitus, hydrochlorothiazide, hypertension, KCNJ1, pharmacogenetics, ROMK1",
author = "Karnes, {J. H.} and McDonough, {C. W.} and Y. Gong and Vo, {T. T.} and Langaee, {T. Y.} and Chapman, {A. B.} and Gums, {J. G.} and Beitelshees, {A. L.} and Bailey, {Kent R} and Del-Aguila, {J. L.} and Boerwinkle, {E. A.} and Pepine, {C. J.} and Turner, {Stephen T} and Johnson, {J. A.} and Cooper-Dehoff, {R. M.}",
year = "2013",
month = "10",
doi = "10.1038/tpj.2012.34",
language = "English (US)",
volume = "13",
pages = "430--436",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment

AU - Karnes, J. H.

AU - McDonough, C. W.

AU - Gong, Y.

AU - Vo, T. T.

AU - Langaee, T. Y.

AU - Chapman, A. B.

AU - Gums, J. G.

AU - Beitelshees, A. L.

AU - Bailey, Kent R

AU - Del-Aguila, J. L.

AU - Boerwinkle, E. A.

AU - Pepine, C. J.

AU - Turner, Stephen T

AU - Johnson, J. A.

AU - Cooper-Dehoff, R. M.

PY - 2013/10

Y1 - 2013/10

N2 - Thiazide-induced potassium loss may contribute to new onset diabetes (NOD). KCNJ1 encodes a potassium channel and one study observed that a KCNJ1 single-nucleotide polymorphism (SNP) was associated with changes in fasting glucose (FG) during hydrochlorothiazide (HCTZ) treatment. We used linear regression to test association of KCNJ1 SNPs and haplotypes with FG changes during HCTZ treatment in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. We used logistic regression to test association of KCNJ1 variation with NOD in HCTZ-treated patients from the International Verapamil SR Trandolapril Study (INVEST). Multivariate regression analyses were performed by race/ethnicity with false discovery rate (FDR) correction. In PEAR blacks, a KCNJ1 SNP was associated with increased FG during HCTZ treatment (beta=8.47, P FDR =0.009). KCNJ1 SNPs and haplotypes were associated with NOD risk in all INVEST race/ethnic groups (strongest association: odds ratio 2.14 (1.31-3.53), P FDR =0.03). Our findings support that KCNJ1 variation is associated with HCTZ-induced dysglycemia and NOD.

AB - Thiazide-induced potassium loss may contribute to new onset diabetes (NOD). KCNJ1 encodes a potassium channel and one study observed that a KCNJ1 single-nucleotide polymorphism (SNP) was associated with changes in fasting glucose (FG) during hydrochlorothiazide (HCTZ) treatment. We used linear regression to test association of KCNJ1 SNPs and haplotypes with FG changes during HCTZ treatment in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. We used logistic regression to test association of KCNJ1 variation with NOD in HCTZ-treated patients from the International Verapamil SR Trandolapril Study (INVEST). Multivariate regression analyses were performed by race/ethnicity with false discovery rate (FDR) correction. In PEAR blacks, a KCNJ1 SNP was associated with increased FG during HCTZ treatment (beta=8.47, P FDR =0.009). KCNJ1 SNPs and haplotypes were associated with NOD risk in all INVEST race/ethnic groups (strongest association: odds ratio 2.14 (1.31-3.53), P FDR =0.03). Our findings support that KCNJ1 variation is associated with HCTZ-induced dysglycemia and NOD.

KW - diabetes mellitus

KW - hydrochlorothiazide

KW - hypertension

KW - KCNJ1

KW - pharmacogenetics

KW - ROMK1

UR - http://www.scopus.com/inward/record.url?scp=84884592019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884592019&partnerID=8YFLogxK

U2 - 10.1038/tpj.2012.34

DO - 10.1038/tpj.2012.34

M3 - Article

VL - 13

SP - 430

EP - 436

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -